​

Iterum Therapeutics Stock (NASDAQ:ITRM)

ForecastRevenueOwnershipFinancialsChartTranscripts
Iterum Therapeutics by TradingView

Previous Close

$0.42

52W Range

$0.36 - $2.10

50D Avg

$0.57

200D Avg

$0.87

Market Cap

$19.32M

Avg Vol (3M)

$951.07K

Beta

2.91

Div Yield

-

ITRM Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 25
Operating Segments$390.00K

Fiscal year ends in Dec 24 | Currency in USD

ITRM Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.70M$-47.47M$-30.38M
Net Income$-24.77M$-38.37M$-44.43M
EBITDA$-18.70M$-34.58M$-39.97M
Basic EPS$-1.26$-2.96$-3.63
Diluted EPS$-1.26$-2.96$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 14, 25 | 8:30 AM
Q2 25Aug 05, 25 | 8:30 AM
Q1 25May 13, 25 | 8:30 AM

Peer Comparison

TickerCompany
PLURPluri Inc.
INTSIntensity Therapeutics, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
RLYBRallybio Corporation
KLTOKlotho Neurosciences, Inc.
QTTBQ32 Bio Inc.
BOLDBoundless Bio, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
ANTXAN2 Therapeutics, Inc.